Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Modified dosing schedule of apolizumab allows higher doses in CLL and ALL

Dec. 19, 2002

Trifunctional bispecific antibody shows potential for B-cell lymphoma

Dec. 18, 2002

TP-38 demonstrates antitumor activity in glioblastoma

Dec. 17, 2002

Potential use of CC-5013 in the treatment of hematological malignancies

Dec. 17, 2002

Disappointing phase III preliminary results for CeaVac in colorectal cancer

Dec. 16, 2002

IDEC-114 reported safe and effective in refractory follicular lymphoma

Dec. 16, 2002

Minimal toxicity reported for SGN-30 in Hodgkin's disease and lymphoma

Dec. 13, 2002

MDX-060 has marked antitumor activity in CD30+ lymphoma-bearing mice

Dec. 11, 2002

Vasogen reports preliminary results from pilot study in CLL

Dec. 11, 2002

Good safety profile reported for IL-13-PE38QQR in malignant glioma

Dec. 10, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...